Oragenics Q2 net loss widens 11.3% to $2.53 million year over year

Reuters2026/08/13 20:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oragenics posted a GAAP net loss of USD 2.53 million, widening 11.3% year over year.
Operating loss widened to USD 2.59 million as total operating expenses climbed 51.24% to USD 2.59 million.
R&D spend more than doubled to USD 1.18 million, driven by higher external regulatory and clinical consulting for ONP-002.
G&A expense rose 11.97% to USD 1.42 million, reflecting about USD 405,000 in higher patent-related costs.
Cash and cash equivalents totaled USD 3.9 million at June 30, 2026; ONP-002 Phase IIa in Australia enrolled 9 participants with no serious adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037749), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oragenics Q2 net loss widens 11.3% to $2.53 million year over year

You may also like

Crypto prices